[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Rutgers, The State University of New Jersey\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":674},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,118,0,25,[9,43,74,99,130,155,184,209,233,257,285,313,336,373,401,421,443,467,485,525,552,580,604,630,650],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100054105","phase-4-effects-of-melatonin-on-sleep-architecture-of-critically-ill-patients-in-the-icu-100054105",false,"NCT07691996","Effects of Melatonin on Sleep Architecture of Critically Ill Patients in the ICU","Inclusion Criteria:\n\n* 18 years or older, admitted to the ICU\n* Expected length of stay of at least 48 hours\n* Not mechanically ventilated\n* Able to take oral medications.\n* Hemodynamically stable as determined by the treating ICU physician\n* Able to provide informed consent or have consent provided by a legally -authorized representative.\n\nExclusion Criteria:\n\n* Mechanically ventilated\n* Currently using melatonin prior to ICU admission,\n* Have neurological conditions that may significantly alter sleep architecture, such as traumatic brain injury, stroke, or severe dementia.\n* Pregnant or lactating individuals\n* Those individuals with a comfort measures-only status","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This is a pilot study to examine the effects of melatonin on the sleep patterns of critically ill patients. Patients will have their sleep patterns measured with a device attached to their head with a headband then be given a dose of melatonin. Their participation in the study will last two days.",[26,27,28,29,30],"Critical Illness","ICU","ICU Hospitalization","Melatonin","Sleep","NOT_YET_RECRUITING","2026-07-09",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":20},"2026-09-01",{"date":39,"type":20},"2028-01",{"name":41,"class":42},"Rutgers, The State University of New Jersey","OTHER",{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100054002","virtual-cycling-environments-for-persons-with-parkinson-disease-100054002","NCT04804202","Virtual Cycling Environments for Persons With Parkinson Disease","Virtual Cycling Environments (VCYCLE) Increases Exercise Intensity of Persons With Parkinson Disease","VCYCLE_PD","Inclusion Criteria:\n\n1. Diagnosis of Parkinson's disease\n2. Hoehn and Yahr stages II-III,\n3. 45-75 years old\n4. able to ride a stationary upright bicycle\n5. able to sign informed consent.\n\nExclusion Criteria:\n\n1. Have a recent history of severe heart disease, severe lung disease, uncontrolled diabetes, traumatic brain injury or neurological disorder other than Parkinson Disease.\n2. Are unable to follow directions or sign a consent form\n3. Do not have adequate vision or hearing ability to see or hear a television\n4. Have unstable medical condition or musculoskeletal disorder such as severe arthritis, recent knee surgery, hip surgery, or any other condition that the investigators determine would impair the ability to ride the bicycle\n5. Have any other medical condition that prevents bicycling\n6. Have moderate depression","45 Years","75 Years",{"count":54,"type":20},60,[56],"NA","This study asks three questions about Persons with Parkinson Disease that use a bicycle for exercise. 1. Does the use of virtual reality increase the intensity and and enjoyment of the experience compared to bicycling without virtual reality? 2. Does the way in which the bicycling (interval compared to continous) is performed affect the experience? 3. How does the way the virtual reality is delivered (with goggles or projected on a screen) affect the experience?",[59],"Parkinson Disease",[61,62,63,64,65],"virtual reality","exercise","cardiovascular intensity","neuromuscular intensity","enjoyment","RECRUITING",{"date":34,"type":35},{"date":69,"type":35},"2021-02-08",{"date":71,"type":20},"2027-12-30",{"name":41,"class":42},2,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":73},"100053827","evaluating-the-use-of-prehospital-lung-ultrasound-in-ems-a-multicenter-pilot-study-100053827","NCT07549334","Evaluating the Use of Prehospital Lung Ultrasound in EMS: A Multicenter Pilot Study","Inclusion Criteria:\n\n* Patient treated by Emergency Medical Services\n* Complaint of dyspnea\n\nAt least one of the following:\n\n* Oxygen saturation \\\u003C94% on room air\n* Abnormal lung sounds\n* Increased work of breathing\n* Pedal edema\n* Orthopnea\n\nExclusion Criteria:\n\n* Pediatric patients (\\\u003C18)\n* Traumatic etiology\n* Cardiac arrest at any point prehospitally\n* No ultrasound-trained paramedic involved in patient's care",{"count":81,"type":20},1000,[56],"The goal of this prospective nonrandomized study is to determine if prehospital lung ultrasound findings result in a change in patient management. This study will look at how lung ultrasound exam improves diagnosis of respiratory distress in patients being treated by Emergency Medical Services, such as patients with heart failure. Additional questions include:\n\n* How well can paramedics obtain and interpret ultrasound images?\n* How does ultrasound use change treatment received by patients?\n* How does ultrasound use impact patient outcomes? Participants will receive a lung ultrasound exam, but otherwise receive standard evaluation and care. Patients who receive ultrasound will be compared to those who did not receive ultrasound for logistical reasons and patients from before the use of ultrasound. Ultrasound will not be withheld from any patient for the purposes of the study.",[85,86],"Congestive Heart Failure(CHF)","Pulmonary Edema",[88,89,90,86,91,92],"Ultrasound","Emergency Medical Services","Pulmonary Ultrasound","Congestive Heart Failure","Paramedic",{"date":34,"type":35},{"date":95,"type":20},"2026-08",{"date":97,"type":20},"2028-12",{"name":41,"class":42},{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":16,"minAge":107,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100645399","sun-safe-together-a-digital-skin-cancer-prevention-intervention-for-adolescents-and-their-parents-100645399","NCT07681791","Sun Safe Together: A Digital Skin Cancer Prevention Intervention for Adolescents and Their Parents","A Digital Skin Cancer Prevention Intervention for Adolescents and Their Parents","Inclusion Criteria:\n\nParents and teens are participating as dyads, meaning both the parent and the teen need to be deemed eligible based on the criteria below to be able to participate.\n\nTeens\n\n* Must be ages 13-17 years\n* Live with study parent equal to or greater than half time in US\n* Have experienced sunburn or indoor tanned in the last year or have a suboptimal sun protection score\n* Have no personal history of melanoma or severe medical condition that prevents participation\n* Have access to smartphone\n* Speak and read English\n\nParents\u002FGuardians\n\n* Must be age 18 or older\n* Live with a teen equal to or greater than half time in US\n* Have a teen who had experienced sunburn or indoor tanned in the last year or have a suboptimal sun protection score\n* Have no personal history of melanoma or severe medical condition that prevents participation\n* Have internet at home, a Facebook account, and be willing to use Facebook daily\n* Have access to smartphone\n* Speak and read English",true,"13 Years",{"count":109,"type":20},104,[56],"The goal of this pilot clinical trial is to learn if a digital intervention to improve sun safety, Sun Safe Together (SST), is feasible and acceptable to teenagers and their parents.",[113],"Skin Cancer Prevention",[115,116,117,118,119,120],"Sun Safety","Teens","Messages","Teen health","Parents","Education","2026-06-30",{"date":123,"type":35},"2026-07-02",{"date":125,"type":20},"2026-06",{"date":127,"type":20},"2027-02",{"name":41,"class":42},1,{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":140,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":73},"100578660","virtual-diabetes-care-for-adults-with-type-2-diabetes-on-medicaid-and-insulin-therapy-100578660","NCT06814184","Virtual Diabetes Care for Adults With Type 2 Diabetes on Medicaid and Insulin Therapy","Nurse-led App Intervention to Improve Glycemic Control in Patients With Insulin-treated Type 2 Diabetes on Medicaid","virtual care","Inclusion Criteria:\n\n* A1C \\>7 for age 18-64, A1C\\>8 for age 65 or older within 12 months prior baseline\n* A1C\\>7 for age 18-64, A1c\\>8 for age 65 or older at baseline\n* Medicaid recipient or dual Medicaid and Medicare recipient\n* Age 18 or older\n* Type 2 diabetes\n* On insulin therapy\n* Owning and using Android or iOS smartphone for at least 6 months\n* English proficiency\n* Adequate vision to read text messages on their current smartphone\n* Smartphone use proficiency. Smartphone proficiency will be self-reported and determined by telephone as the ability to use a smartphone in ways other than emailing, texting, and making phone calls.\n\nExclusion Criteria:\n\n* Pregnancy\n* Patients with cognitive impairment who will be screened with the Six-Item Screener to Identify Cognitive Impairment Among Potential Research Subjects.","90 Years",{"count":54,"type":20},[56],"This 12-month pilot tests a nurse-led, app-based intervention to improve diabetes self-management for Medicaid patients. It includes MyChart messaging to give education, phone help on problem-solving with clinicians, and using a diabetes app to track data. The study aims to enhance self-management behaviors through health technology.",[143],"Type 2 Diabetes",[145,146,147,148],"diabetes app","behavioral intervention","self-management","diabetes",{"date":123,"type":35},{"date":151,"type":35},"2026-04-01",{"date":153,"type":20},"2028-12-01",{"name":41,"class":42},{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":16,"minAge":162,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":21,"phases":165,"briefSummary":168,"conditions":169,"keywords":173,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":183},"100645002","phase-2-exercise-and-intranasal-insulin-in-type-2-diabetes-100645002","NCT07675499","Exercise and Intranasal Insulin in Type 2 Diabetes","Effects of Intranasal Insulin Plus Exercise Training on Brain Blood Flow, Neuronal Insulin Signaling, and Cognition in Adults With Type 2 Diabetes","Inclusion Criteria:\n\n* Male or female 55-80 years old\n* Type 2 diabetes diagnosis or confirmation HbA1c \\>6.5% and fasting glucose \\>126 mg\u002Fdl\n* Individuals prescribed metformin, GLP-1 agonists (oral\u002Finjectable), TZDs, DPP-IV inhibitors, Acarbose, SGLT-2 inhibitors \\>6 months.\n* MOCA ≥26\n* Body mass index (BMI) ≥25 and ≤40 kg\u002Fm2\n* Not diagnosed with Type 1 diabetes\n* Not currently engaged in \\\u003C90 min\u002Fwk of exercise\n\nExclusion Criteria:\n\n* A diagnosis of dementia\n* Neurologic disease (e.g. Parkinson's, autonomic neuropathy, etc.)\n* Intolerance to insulin\n* Morbidly obese patients (BMI \\>40 kg\u002Fm2) and lean patients (BMI \\\u003C25 kg\u002Fm2)\n* \\>2 kg weight change in past 6 months\n* Participants who have been recently active (\\>90 min of moderate\u002Fhigh intensity exercise)\n* Individuals who are smokers or who have quit smoking (\\\u003C2 years)\n* Hypertriglyceridemia (400 mg\u002Fdl) and hypercholesterolemic (\\>260 mg\u002Fdl) subjects\n* Uncontrolled Hypertensive (\\>160\u002F100 mmHg)\n* Participants with a history of significant metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with or alter the outcome measures, or impact subject safety\n* Pregnant (as evidenced by positive pregnancy test) or nursing women\n* Participants with contraindications to participation in an exercise training program\n* Major psychiatric disorders (e.g. psychosis, bipolar disorder, major depression, alcohol\u002Fsubstance abuse)\n* History of head trauma or loss of consciousness in last 5 years.\n* Known contraindications for MR imaging:\n\n  * History of head trauma or neurosurgery, or neurological disorder (other than headaches or peripheral nerve disease) as these may impact neuroimaging results.\n  * Ferrous material implanted in or on the body, including flakes or filings, surgical clips, bullets, or electrical devices such as a pacemaker, or nonremovable ferrous jewelry (fillings in teeth and permanent retainers are permitted).\n  * Fillings and permanent retainers do not provide a safety risk and are not general exclusions. However, upper retainers may cause artifacts in ventral frontal regions and therefore may be an exclusion for some studies.\n  * Individuals with surgical pins or plates above the neck are excluded. Surgical pins or plates below the neck are exclusions, except when the material is fixed to bone, and considered acceptable by the Reference Manual for Magnetic Resonance Safety. Implants and Devices, 2020 Edition. Almost all recent orthopedic implants are made of materials that are not ferromagnetic and therefore are safe for scanning, and even though some screws are still made of ferromagnetic materials these are firmly screwed into bone. In cases where the material is unknown or deemed unsafe for scanning by the Reference Manual for Magnetic Resonance Safety. Implants and Devices the participant will be excluded.\n  * History of eye injury involving metallic materials, shavings in eyes, or welding without a face mask\n  * Lead\u002Firon tattoos\n  * Claustrophobia (history of significant anxiety in closed places).\n  * Back problem that would prevent the subject from laying still comfortably for up to 90 minutes.\n  * Deafness","55 Years","80 Years",{"count":54,"type":20},[166,167],"PHASE2","PHASE3","About 6.5 million adults in the United States who are 65 or older have dementia.\n\nWhile the exact cause of dementia is not known, it may be due to changes in the brain. Further, risk may be higher when the brain does not respond to insulin. Indeed, brain insulin resistance has emerged as a pathologic factor affecting memory, executive function as well as systemic glucose control. Regular aerobic exercise may help reduce the risk of dementia by increased blood flow to the brain and help the brain respond better to insulin. In addition, giving insulin through a nose spray (called intranasal insulin) may also help with thinking and memory. However, it is unknown if using both exercise and intranasal insulin is best for the brain.",[143,170,171,172],"Insulin Sensitivity\u002FResistance","Cognition","Brain Blood Flow",[174,175],"Exericse","Intranasal Insulin","2026-06-26",{"date":121,"type":35},{"date":179,"type":20},"2026-08-03",{"date":181,"type":20},"2029-05-31",{"name":41,"class":42},4,{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":106,"sex":191,"minAge":192,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":21,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":73},"100641565","developing-and-implementing-hpv-screened-100641565","NCT07657104","Developing and Implementing HPV SCREENED","Developing and Implementing HPV SCREENED (Self-Collection REach and ENgagement in Emergency Departments) to Improve Cancer Equity","Inclusion Criteria:\n\n* biological women,\n* no prior hysterectomy or cervical cancer,\n* not pregnant,\n* last Pap \\>3 years, last co-test \\>5 years, or last HPV alone test \\>5 years,\n* speak English or Spanish,\n* has a working cellphone,\n* NJ residency\n* ED patient\n\nExclusion Criteria:\n\n* currently pregnant (as diagnostic procedures for cervical cancer are often deferred during pregnancy);\n* previous hysterectomy;\n* previous diagnosis of cervical cancer;\n* current menses","FEMALE","30 Years","65 Years",{"count":195,"type":20},100,[56],"This study will assess the feasibility of implementing HPV self-sampling as a primary cervical cancer screening strategy for under-screened women in the emergency department (ED). Eligible participants will receive education and an HPV self-sampling kit to complete in the ED. Individuals with HPV-positive results will be guided to follow-up care at a local clinic.",[199,200],"Cervical Cancer Screening","Human Papilloma Virus","2026-06-17",{"date":203,"type":35},"2026-06-18",{"date":205,"type":20},"2026-07-01",{"date":207,"type":20},"2027-09-30",{"name":41,"class":42},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":21,"phases":218,"briefSummary":219,"conditions":220,"keywords":224,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":129},"100600211","phase-2-jaw-muscle-pain-post-wisdom-molar-surgery-100600211","NCT07094542","Jaw Muscle Pain Post Wisdom Molar Surgery","Temporo-masseteric Nerve Block in Post-wisdom Tooth Extraction Pain- a Randomized Study","Inclusion Criteria:\n\nAll patients recommended extraction\u002Fs of at least 1 lower wisdom (third) molar that is partially\u002Ffully 'impacted' under intravenous sedation, are eligible to participate in this study so long as they\n\n* are 18 years or older,\n* are healthy,\n* have no cognitive\u002Fintellectual disability,\n* have no past\u002Frecent pain or reduced range of motion in their jaw joint\u002F muscle complex, no trauma or surgery in their jaw region.\n* have an electronic device such as a smart phone or a tablet\u002F computer with internet connection.\n* are willing to participate in the study and not be excluded by the following criteria below.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Compromised ability to guard their self-interest, for e.g., prisoners, children, pregnant women, patients with intellectual\u002Fcognitive disability are not enrolled in the study.\n* Those patients who present with infection\u002Finflammation involving the third molars slated for extractions, on the day of their procedure, may not take part in the study.\n* Those who have had opioid pain medication\u002Fs in the past 3 months to address short term or long-standing pain, or those who are on long term prescription of anti-inflammatory pain medication, are unable to participate.\n* Those with long standing painful limitation of movement of the jaw joint or muscles.\n* Those patients who are allergic to\u002Funable to tolerate either the dental local anesthetic or its components, opioids, acetaminophen or ibuprofen also may not take part in the study",{"count":217,"type":20},80,[166],"The proposed design is a triple-blind, placebo-controlled randomized prospective phase II trial to assess the feasibility of employing the Temporo-masseteric Nerve Block (TMNB) injection to decrease jaw muscle pain, overall pain, improve mouth opening and minimize pain medication consumption. 80 participants undergoing lower third molar removal under sedation will be enrolled. Those who develop significant jaw muscle pain on the following day will be randomized to receive either the TMNB injection or a placebo. Daily ecological momentary assessments (EMAs) will be collected reflecting elements of patient experience for all participants. On Day 8, participants return for an end-of-study evaluation and return their unused pain medications. Up to 40 participants who are randomized to receive TMNB\u002Fplacebo will be recruited to participate in a qualitative interview regarding their experience.",[221,222,223],"Post Operative Pain","Impacted Third Molar Tooth","Muscle Pain",[225,226],"Temporo-masseteric Nerve Block","Jaw muscle pain",{"date":203,"type":35},{"date":229,"type":20},"2026-09",{"date":231,"type":20},"2030-05",{"name":41,"class":42},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":21,"phases":242,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":129},"100430102","phase-2-twin-block-pain-medications-and-third-molar-extractions-100430102","NCT04880707","Twin Block, Pain Medications and Third Molar Extractions","Myogenous Face Pain Following Third Molar Extractions Under Intravenous Sedation","Inclusion Criteria:\n\n* All patients requiring extraction\u002Fs of at least 1 lower wisdom (third) molar that is partially\u002Ffully 'impacted', under intravenous sedation, are eligible to participate in this study so long as they\n\n  1. are older than 18 years of age,\n  2. are healthy,\n  3. have no cognitive\u002Fintellectual disability,\n  4. have no past\u002Frecent pain or reduced range of motion in their jaw joint\u002F muscle complex, no trauma or surgery in their jaw region.\n  5. have an electronic device such as a smart phone or a tablet\u002F computer with internet connection.\n  6. are willing to participate in the study and not be excluded by the following criteria below.\n\nExclusion Criteria:\n\n* Any patients, even if satisfying the criteria above, may not take part if they have any of the following:\n\n  1. Compromised ability to guard their self-interest, for e.g., prisoners, children, pregnant women, patients with intellectual\u002Fcognitive disability are not enrolled in the study.\n  2. Those patients who present with infection\u002Finflammation involving the third molars slated for extractions, on the day of their procedure, may not take part in the study.\n  3. In addition, those who have had opioid pain medication\u002Fs in the past to address short-term or long-standing pain, or those who are on long term prescription of anti-inflammatory pain medication, are unable to participate.\n  4. Those with long standing pain of the jaw joint or muscles.\n  5. Finally, those patients who are allergic to\u002Funable to tolerate either the dental local anesthetic or its components, opioids, acetaminophen ('Tylenol') or ibuprofen ('Motrin' or 'Advil') also may not take part in the study.",{"count":241,"type":20},48,[166],"Each year, over 3.5 million, mostly, healthy young adults, have their third molar teeth ('wisdom teeth') removed under sedation and are often given opioid prescriptions for managing their pain. Wisdom molar removal is one of the most common reasons for opioid prescriptions to be given to adolescents. There is a national thrust to reduce both the dose and the duration of such opioid prescriptions because even short-term opioid exposures increase risk for narcotic addiction and misuse. Non-opioid options to manage pain will still allow for sufficient pain control without risking addiction, and hence, a fundamental component of our response to combat the current national opioid crisis.\n\nThe investigators are going to study a promising option- the Twin Block dental anesthetic injection. The Twin block involves injecting the standard dental numbing medication in a way that 'numbs' the 'jaw-clencher' muscles on the side of the face. The investigators found that the Twin block relieved jaw pain stemming from these muscles, in a quick and sustained manner, even in patients whose pain following wisdom tooth removal primarily came from 'taut' and tender jaw-clencher muscles. However, what is not known is- how often do patients who have their wisdom teeth removed under sedation, end up in significant pain from taut and tender jaw-clencher muscles? Will using the twin block effectively reduce pain in such patients? In this pilot study, the investigators will examine wisdom molar extraction patients one day after their procedure. Those with significant pain (pain rated ≥ 5 on a 0-10 scale) in their jaw-clencher muscles, will get either the Twin block injection or a placebo. The investigators will track both 1) pain before and after the injection, and 2) pain medication usage over a 7-day period to see if both pain and opioid dosage come down with the Twin block. This study can support a simple, safe and inexpensive means to reduce pain after a common procedure.",[245],"Acute Pain",[247,248,249],"Twin block","Prescription opioids","Acute post-extraction pain",{"date":251,"type":35},"2026-06-22",{"date":253,"type":35},"2024-03-11",{"date":255,"type":20},"2026-12",{"name":41,"class":42},{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":106,"sex":16,"minAge":17,"maxAge":163,"enrollmentInfo":264,"targetDuration":4,"studyType":21,"phases":265,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":129},"100641540","early-phase-1-gait-adaptation-study-100641540","NCT07660601","Gait Adaptation Study","Integrative Training Approach for Inducing Neuroplasticity in Multiple Sclerosis","Inclusion Criteria:\n\n* Age 18 to 80 yrs Clinically definite MS diagnosis Ability to attend to computer screen and follow instructions in English which will be assessed by MiniMental test requiring a participant to score \\>24 (out of 30 max score) Right-handed as determined by research diagnostic criteria of the Edinburgh Handedness Inventory (Oldfield 1971) Self report of normal or corrected-to-normal vision\n\nExclusion Criteria Psychiatric disorders, only those requiring treatment because the medications may affect brain activation Neurological disorder that may affect cognition, balance, and\u002For physical wellness such as brain injury, or stroke.\n\nOrthopedic injuries or neuromuscular disorder that may affect balance or mobility Engagement in other cognitive or physical training program while enrolled in this study Ongoing relapse (new or returning neurological symptoms) or steroid treatment during the 30 days preceding enrollment",{"count":19,"type":20},[266],"EARLY_PHASE1","This pilot study proposes a clinical trial to target treatment of sensorimotor and cognitive deficits in persons with Multiple Sclerosis (pwMS). The proposal has the potential to promote neuroplasticity and induce re-normalization in brain to muscle (cortico-muscular) connectivity (BMC) and within brain connectivity via an integrative training approach. Preliminary data and published work are available to inform specific aspects of the proposed trial, along with the general rationale for exploring the suggested rehabilitation approach. However, there is a gap in research on the effects of training that uses the proposed approach via a clinical trial (of any phase) in pwMS to support the rationale for exploring the suggested rehabilitation training approach. Moreover, there is no pilot data on the training itself in the same population. This study will examine the behavioral deficits and neural characteristics in children with MS and two other related conditions (Myelin Oligodendrocyte Glycoprotein (MOG) and Nueromyelitis Optica Spectrum Disorder (NMOSD)) to understand if they would benefit from rehabilitation training conditions tested in aims 1 and 2. The overall long term goal is to improve rehabilitation training conditions for both adults and children with MS.",[269],"Aging",[271,272,273,274,275,276,277],"cognition","mobility","impairment","electrophysiology","gait","gait adaptation","daily living","2026-06-16",{"date":251,"type":35},{"date":281,"type":35},"2025-01-31",{"date":283,"type":20},"2028-07-20",{"name":41,"class":42},{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":106,"sex":16,"minAge":17,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":21,"phases":295,"briefSummary":296,"conditions":297,"keywords":300,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":307,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":129},"100622025","finding-emotional-empowerment-and-lifelong-strength-100622025","NCT07378254","Finding Emotional Empowerment and Lifelong Strength","Co-Producing a Trauma and Substance Use Mental Health Literacy Intervention","FEELS","Inclusion Criteria:\n\n1. Self-identify as Black or African American\n2. Be between the ages of 18 and 35 years old\n3. Endorse previous lifetime trauma exposure\n4. Participants must speak English\n5. Participants are capable of giving informed consent and capable of complying with study procedures.","35 Years",{"count":217,"type":20},[56],"This study will build a partnership with a Community Advisory Board to co-produce, and then pilot test, a theory-guided mental health literacy intervention focused on trauma and substance use. Participants will take part in educational group sessions for 12 weeks and complete assessments at baseline and two follow-up time points (mid-intervention and post-intervention). Intervention participants will be randomly invited to post-study focus groups to gather feedback on their experiences in the program.",[298,299],"Trauma and Stressor Related Disorders","Substance Use",[301,302,303,304,305,306],"mental health literacy","trauma","substance use","psychoeducation","Black and African American","young adults",{"date":203,"type":35},{"date":309,"type":35},"2026-03-10",{"date":311,"type":20},"2028-06",{"name":41,"class":42},{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":16,"minAge":320,"maxAge":321,"enrollmentInfo":322,"targetDuration":4,"studyType":21,"phases":324,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":129},"100366002","refinements-of-functional-communication-training-100366002","NCT04045600","Refinements of Functional Communication Training","Stimulus Control Refinements of Functional Communication Training","Inclusion Criteria:\n\n* Boys and girls from ages 3 to 17\n* Destructive behavior that occurs at least 10 times a day despite previous treatment\n* Destructive behavior reinforced by social consequences like attention (FCT is not appropriate for automatically reinforced destructive behavior)\n* On a stable psychoactive drug regimen for at least 10 half-lives per drug or drug free\n* Stable educational plan and placement with no anticipated changes during the child's treatment\n\nExclusion Criteria:\n\n* Patients who do not meet the inclusion criteria\n* Patients currently receiving 15 or more hours per week of treatment for their destructive behavior\n* DSM-5 diagnosis of Rett syndrome or other degenerative conditions (e.g., inborn error of metabolism)\n* A comorbid health condition or major mental disorder that would interfere with study participation\n* Occurrence of SIB during study assessments that presents a risk of serious or permanent harm (e.g., detached retinas) based on our routine clinical-risk assessment\n* Patients requiring drug-treatment changes, but the experimenters will invite these patients to participate if they meet inclusion criteria after drug regimen is stable.","3 Years","17 Years",{"count":323,"type":20},24,[56],"Although treatments for problem behavior, like functional communication training (FCT), can be highly effective in the clinic, changes in the way the FCT is implemented (e.g., when transferring treatment to the home, when teachers implement treatment with poor fidelity) can result in treatment relapse. The goal of this study is to evaluate whether using treatment signals and gradually introducing materials from natural contexts can help mitigate treatment relapse during context changes and poor treatment-integrity scenarios.",[327,328],"Aggression","Self-injurious Behavior","2026-06-15",{"date":201,"type":35},{"date":332,"type":35},"2021-05-03",{"date":334,"type":20},"2026-12-31",{"name":41,"class":42},{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":16,"minAge":344,"maxAge":321,"enrollmentInfo":345,"targetDuration":4,"studyType":21,"phases":347,"briefSummary":348,"conditions":349,"keywords":352,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":129},"100578949","speech-and-arm-combined-exergame-100578949","NCT06817941","Speech and Arm Combined Exergame","Enhancing Rehabilitation Outcomes in Cerebral Palsy Through Gamified Multidisciplinary Interventions: Integrating Speech and Upper Extremity Motor Therapy","SPACE","Inclusion Criteria:\n\n* (1) diagnosis of CP\n* (2) age between 8-17 years (i.e., pediatric age)\n* (3) use speech as the primary mode of communication\n* (4) mild to moderate dysarthria\n* (5) Manual Ability Classification System (MACS) level I to III\n* (6) Gross Motor Function Classification System (GMFCS) level I to IV\n* (7) mild to moderate muscle spasticity of the arm with a Modified Tardieu Scale of 0-3\n* (8) pass bilateral pure-tone hearing screening at 25 dB HL (at 500, 1000, 2000, and 4000 Hz)\n* (9) able to follow simple task-related directions, including repeating short phrases.\n\nExclusion Criteria:\n\n* (1) severe vision impairment that limits the child's ability to interact with the entire computer screen\n* (2) dyskinetic CP or spastic diplegia\n* (3) English is not their first or primary language.","8 Years",{"count":346,"type":20},15,[56],"The purpose of this study is to develop innovative home therapy games to train the weak arm and improve speech intelligibility (clarity) of children with hemiplegia from cerebral palsy. The investigators are exploring the effects of these therapy games and how they change the children's speech, hand movement, and brain activation.\n\n15 children who are 8-17 years old will be recruited for this study. These children should have a diagnosis of cerebral palsy, mild to moderate speech issues but use speech as the primary mode of communication, mild to moderate movement difficulty and muscle spasticity, adequate hearing (pass a hearing screening), and be able to follow simple task-related directions.\n\nChildren who have severe vision impairment that limits the child's ability to interact with the entire computer screen, have severe arm weakness so they cannot move their arm enough to interact with the computer games, have severe increase in tone in their weak arm, or have difficulty following instructions or paying attention to computer video games for at least 10 minutes cannot participate in this study.\n\nThe therapy games will take 8 weeks to finish at home. Each child will play these games for 30 minutes each day, 5 days per week.\n\nIn addition, children will come to the lab 4 times for speech and hand movement assessment: (1) 1st assessment takes place immediately before the child start to play the video games. (2) 2nd assessment takes place 4 weeks (midpoint) after the child starts to play the games. (3) 3rd assessment takes place immediately after the video games are finished. (4) 4th assessment takes place 6 weeks after the video games are finished.\n\nEach assessment should take about 2 hours to complete in the Rutgers movement lab or at Rutgers SLP Clinic.\n\nA total of 15 children will take part in this research study. The research will last for 2 years overall.",[350,351],"Cerebral Palsy (CP)","Dysarthria",[353,354,355,356,357,358,359,360,361,362,363,364],"cerebral palsy","children","dysarthria","motor speech disorder","upper extremity","arm weakness","intervention","video games","fNIRS","neuroimaging","therapy","rehabilitation","2026-06-10",{"date":367,"type":35},"2026-06-12",{"date":369,"type":35},"2025-06-01",{"date":371,"type":20},"2027-08",{"name":41,"class":42},{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":16,"minAge":381,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":21,"phases":384,"briefSummary":385,"conditions":386,"keywords":391,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":394,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":400},"100469858","behavioral-exposure-for-introceptive-tolerance-rct-100469858","NCT05398276","Behavioral Exposure for Introceptive Tolerance RCT","A Tailored Exposure Intervention for Exercise Anxiety and Avoidance in Cardiac Rehabilitation","BE-FIT","Inclusion Criteria:\n\n1. ≥ 40 years of age\n2. Elevated exercise anxiety (score of ≥ 30 on ESQ-18)\n3. Low active (\\\u003C 90 min self-reported moderate-to-vigorous intensity physical activity\u002Fday in past three months)\n4. Medically approved cardiac rehabilitation\n5. English proficiency\n\nExclusion Criteria:\n\n1. Evidence of cognitive impairment (≤ 23 on Montreal Cognitive Assessment; MoCA)\n2. Severe disabling chronic medical and\u002For psychiatric comorbidities determined on a case-by-case basis that prevents safe or adequate participation\n3. Expectation that patient will not live through study periods","40 Years",{"count":383,"type":20},146,[56],"Behavioral Exposure for Interoceptive Tolerance (BE-FIT) is a mechanism-informed behavioral intervention to target exercise anxiety. The three primary components of BE-FIT include: (1) exposure to feared bodily sensations and exercise; (2) prevention of safety behavior use before\u002Fduring\u002Fafter exercise, and (3) use of a wrist-worn activity monitor for physical activity (PA) feedback and activity goal setting. Evidence from the investigators' Stage I trial indicated that BE-FIT is feasible, acceptable, and safe and produced reductions in exercise anxiety and increased exercise outcomes (short-term moderate-to-vigorous intensity physical activity and steps\u002Fday). The investigators' present aim is to conduct a Stage II randomized-controlled trial to further evaluate the efficacy of BE-FIT in decreasing exercise anxiety in cardiac rehabilitation (CR) patients and examine whether changes in this target yield successive changes in exercise adherence outcomes.",[387,388,389,390],"Exercise Sensitivity","Introceptive Exposure","Anxiety","Cardiac Rehabilitation",[387,388,392,393],"Kinesiophobia","Acceptance and Commitment Therapy",{"date":367,"type":35},{"date":396,"type":35},"2022-05-03",{"date":398,"type":20},"2027-02-28",{"name":41,"class":42},3,{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":191,"minAge":17,"maxAge":138,"enrollmentInfo":409,"targetDuration":4,"studyType":21,"phases":410,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":418,"leadSponsor":420,"locationsCount":129},"100642812","adaptive-daily-mr-guided-adjuvant-pelvic-therapy-endometrial-cancer-100642812","NCT07643012","Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer","Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer: A Phase I\u002FII Feasibility Study","ADAPT-EC","Inclusion Criteria:\n\n1. Histologically confirmed endometrial carcinoma (endometrioid, serous, clear cell, carcinosarcoma, or dedifferentiated histology).\n2. Indication for adjuvant pelvic radiotherapy (± vaginal brachytherapy) for HIR defined by the ASTRO guidelines and GOG-99(7, 9) :\n3. Age\n4. High-grade histology (grade 2-3)\n5. Depth of myometrial invasion\n6. LVSI\n7. Positive pelvic nodes\n8. Cervical stromal invasion\n9. Presence of poor prognostic molecular markers\n10. Age ≥18 years.\n11. Ability to provide informed consent.\n12. Eligible to receive adjuvant systemic therapy, if indicated, with a minimum 3-week interval between chemotherapy and radiotherapy.\n13. Willing and able to complete EORTC QLQ-C30 and EN-24 questionnaires in a validated language version.\n\nExclusion Criteria:\n\n1. Prior pelvic radiotherapy.\n2. Contraindication to pelvic radiotherapy (e.g., active connective tissue disorder or inflammatory bowel disease).\n3. Presence of a hip prosthesis that would compromise treatment planning or delivery.\n\n   \\-",{"count":19,"type":20},[56],"To evaluate the safety, tolerability, and preliminary efficacy of moderately hypofractionated (15-fraction) MR-guided adaptive pelvic IMRT in patients with endometrial cancer.",[413],"Endometrial Cancer","2026-06-09",{"date":416,"type":35},"2026-06-11",{"date":125,"type":20},{"date":419,"type":20},"2029-06",{"name":41,"class":42},{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":21,"phases":429,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":440,"leadSponsor":442,"locationsCount":4},"100540313","examining-the-health-effects-of-npower365-among-black-same-gender-loving-men-100540313","NCT06315218","Examining the Health Effects of NPOWER365 Among Black Same Gender Loving Men","Inclusion Criteria:\n\n1. Identify as Black or African American, regardless of ethnicity\n2. Identify as male, regardless of sex assigned at birth\n3. Are living with HIV and prescribed a daily ART regimen\n4. Are age ≥ 18;\n5. Have sex with men\n6. Own an internet-connected device (e.g., smartphone, tablet)\n7. Reside in the Atlanta-area EHE jurisdictions.\n\nExclusion Criteria:\n\n1. Lack of English fluency\n2. Past participation in the pilot.",{"count":428,"type":20},350,[56],"This research study aims to test the effectiveness, reach, and maintenance over time of the NPOWER365 HIV care intervention for Black men who have sex with men (BMSM) living with HIV. NPOWER365 is a BMSM community-developed multicomponent intervention that aims to: 1) Support daily health promotion via HIV health education and health maintenance reminders; 2) Foster positive social connections among BMSM via online moderated forums, interpersonal chats, and community calendars; 3) Connect clients to BMSM-affirming healthcare, including HIV treatment and mental healthcare; 4) Provide resources for housing, transportation, and other economic empowerment.",[432,433,434,435,436],"Sexual and Gender Minorities","Social Stigma","Medication Adherence","Depressive Symptoms","Anxiety Symptoms","2026-06-08",{"date":365,"type":35},{"date":95,"type":20},{"date":441,"type":20},"2028-04",{"name":41,"class":42},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":16,"minAge":320,"maxAge":321,"enrollmentInfo":450,"targetDuration":4,"studyType":21,"phases":452,"briefSummary":453,"conditions":454,"keywords":456,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":464,"leadSponsor":466,"locationsCount":73},"100607455","phase-2-impact-of-rada16-use-on-outcomes-following-tonsillectomy-in-children-100607455","NCT07188779","Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children","RADA16 for Ped","Inclusion Criteria:\n\nChildren aged 3-17 years undergoing tonsillectomy +\u002F- adenoidectomy CPT codes\n\n* 42820 (Tonsillectomy and adenoidectomy; younger than age 12)\n* 42821 (… age 12 or over)\n* 42825 (Tonsillectomy; primary or secondary; younger than age 12)\n* 42826 (… age 12 or over)\n* 42830 (Adenoidectomy, primary; younger than age 12)\n* 42831 (… age 12 or over)\n* 42835 (Adenoidectomy; secondary; younger than age 12)\n* 42836 (… age 12 or over)\n\nExclusion Criteria:\n\n* Children with bleeding disorders or other hematologic malignancy or taking anticoagulant medications Developmental delay affecting pain reporting Children with known allergies to RADA16 components Children with prior tonsillectomy or tonsillotomy Children undergoing tonsillectomy with concern for cancer, Children taking opioids chronically prior to surgery, Anyone pregnant women, incarcerated individuals, children unable to speak English or Spanish",{"count":451,"type":20},134,[166],"The purpose of the research is to determine if RADA16 (also known as PuraStat®, PuraGel®, or PuraSinus®) improves patient outcomes following pediatric tonsillectomy procedures. Researchers will compare application of device RADA16 to application of no device to see if RADA16 works to treat post tonsillectomy hemorrhage.Participants will:\n\nUndergo tonsillectomy procedure. Receive and fill out a survey sent via email every 2 days following their procedure for 15 days, plus an additional survey on day 30, and track their symptoms.",[455],"Postoperative Pain",[457,458,459,460],"tonsillectomy","adenoidectomy","hemostasis","postop complications","2026-06-07",{"date":414,"type":35},{"date":205,"type":20},{"date":465,"type":20},"2027-12-01",{"name":41,"class":42},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":21,"phases":475,"briefSummary":476,"conditions":477,"keywords":478,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":479,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":73},"100597592","phase-3-rada16-for-adult-tonsillectomy-100597592","NCT07060495","RADA16 for Adult Tonsillectomy","Use of Novel Self-assembling RADA-16 Peptide Matrix to Decrease Postoperative Epistaxis for Tonsillectomy Surgeries","Inclusion criteria:\n\nAdults undergoing tonsillectomy (CPT codes)\n\nExclusion criteria:\n\nPatients undergoing adenoidectomy or uvulopalatopharyngoplasty in addition to tonsillectomy\n\nPatients who have had prior tonsillectomy or tonsillotomy\n\nPatient undergoing tonsillectomy with concern for malignancy\n\nPatients who are on opioids chronically prior to surgery\n\nPatients with an additional indication for pain management (i.e. unrelated to tonsillectomy)\n\nPatients who have been diagnosed with a bleeding disorder or hematologic malignancy\n\nPatients who are on anticoagulants\n\nThe following at-risk populations:\n\nAnyone under age 18\n\nPregnant women\n\nPrisoners\n\nAdults unable to consent (anyone lacking capacity)",{"count":451,"type":20},[167],"The purpose of the research is to determine if RADA16 (also known as PuraStat®, PuraGel®, or PuraSinus®) improves patient outcomes following tonsillectomy procedures.\n\nResearchers will compare application of device RADA16 to application of no device to see if RADA16 works to treat post tonsillectomy hemorrhage.\n\nParticipants will:\n\n* Undergo tonsillectomy procedure.\n* Receive and fill out a survey sent via email every 2 days following their procedure for 15 days and track their symptoms.",[455],[457,459,460],{"date":365,"type":35},{"date":481,"type":35},"2025-09-12",{"date":483,"type":20},"2026-12-01",{"name":41,"class":42},{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":491,"eligibilityCriteria":492,"healthyVolunteers":12,"sex":16,"minAge":381,"maxAge":4,"enrollmentInfo":493,"targetDuration":4,"studyType":21,"phases":494,"briefSummary":495,"conditions":496,"keywords":499,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":129},"100642776","frost-stern-trial-a-trial-of-intraoperative-cryoablation-for-post-operative-pain-management-after-full-sternotomy-100642776","NCT07637370","FROST-STERN Trial: A Trial of Intraoperative Cryoablation for Post Operative Pain Management After Full Sternotomy","FROST-STERN: Functional Recovery and Opioid Sparing Technique for STERNotomy A Randomized Trial of Intraoperative Intercostal Cryoablation for Postoperative Pain Management Following Full Sternotomy","FROST-STERN","Inclusion Criteria:\n\n* Age: Adults aged 40 and above no upper limit.\n* Surgical Plan: Undergoing first-time elective cardiac surgery via full median sternotomy (e.g., CABG, AVR, MVR).\n* Cognitive Status: Ability to understand and provide informed consent and utilize a Numerical Rating Scale (NRS) for pain.\n* Baseline Pain: Preoperative chronic pain score of \\\u003C 3\u002F10.\n\nExclusion Criteria:\n\n* Redo Sternotomy: Previous cardiac surgery (due to adhesions and altered anatomy).\n* Opioid Tolerance: Preoperative daily opioid use for \\>4 weeks (to avoid confounded MME requirements).\n* Neurological Conditions: Pre-existing intercostal neuralgia, peripheral neuropathy, or significant psychiatric disorders.\n* Emergency Cases: Hemodynamically unstable patients or those requiring emergency \"crash\" surgery.\n* Allergies: Known hypersensitivity to local anesthetics (if used in the control arm).\n* Anatomical Barriers: Severe chest wall deformities or extensive pleural adhesions.",{"count":195,"type":20},[56],"Background and Rationale: Open-heart surgery via a median sternotomy is associated with severe acute postoperative pain. This pain can impair a patient's ability to take deep breaths and cough effectively which increases the risk of postoperative lung complications such as atelectasis (collapsed lung) or pneumonia. Traditional pain management protocols rely heavily on opioid medications, which carry systemic side effects including respiratory depression, sedation, and nausea. While short-acting regional nerve blocks are helpful, their effects often wear off within the first 24 hours. The result is a suboptimal duration of pain relief for the remaining critical early recovery window. Intra-operative intercostal nerve cryoablation (temporary nerve freezing) offers a prolonged, localized, and non-opioid alternative. By temporarily interrupting pain signals along the chest wall, this technique may preserve early respiratory function and reduce systemic narcotic requirements during acute recovery.\n\nStudy Objective:The objective of this study is to evaluate whether adding bilateral intra-operative intercostal nerve cryoablation (levels T2 through T6) improves the recovery of pulmonary function and reduces acute pain in patients undergoing elective cardiac surgery via a full median sternotomy.\n\nStudy Design:This is a prospective, randomized, double-blind, sham-controlled, single-center trial. A total of 100 adult patients scheduled for elective first-time cardiac surgery (such as coronary artery bypass grafting or valve replacement) will be randomized in a 1:1 ratio into either an intervention or control group.\n\nIntervention Group: Patients will receive bilateral intraoperative intercostal nerve cryoablation at levels T2-T6 from within the surgical field prior to sternal closure.\n\nControl Group: Patients will receive standard-of-care multimodal analgesia. Patients, clinical staff managing postoperative care, and data assessors will be fully blinded to the treatment assignment.\n\nPrimary Outcome:Pulmonary Function Recovery (FEV1 and Incentive Spirometry): Measured as the percentage of the patient's preoperative baseline Forced Expiratory Volume in 1 second (FEV1) and incentive spirometry recovered at 48 hours postoperatively.\n\nKey Secondary Outcomes:\n\nCumulative postoperative opioid consumption (measured in Morphine Milligram Equivalents, or MME) during the first 72 hours.\n\nSubjective pain intensity scores at rest and during deep inspiration\u002Fcoughing (using a 0-10 Numerical Rating Scale) at 12, 24, 48, and 72 hours.\n\nKey recovery milestones, including time to first extubation, intensive care unit (ICU) length of stay, and total hospital length of stay.\n\nIncidence of long-term or chronic post-sternotomy pain syndrome at 3 and 6 months follow-up.",[497,498,455],"Pulmonary Dysfunction","Median Sternotomy Recovery",[500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517],"cryoablation","cryoanalgesia","nonopioid analgesia","median sternotomy","intercostal nerve block","cryoneurolysis","cardiac surgery","CABG","cardiac valve replacement","post operative pain","FEV1","enhanced recovery after surgery ERAS","MME","Opioid Sparing Effect","Post surgical neuralgia","chronic post sternotomy pain","allodynia","nerve regeneration","2026-06-04",{"date":414,"type":35},{"date":521,"type":20},"2026-07-15",{"date":523,"type":20},"2028-08",{"name":41,"class":42},{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":16,"minAge":532,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":21,"phases":535,"briefSummary":536,"conditions":537,"keywords":539,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":129},"100619750","cigarette-filter-study-100619750","NCT07348679","Cigarette Filter Study","A Randomized Trial of Charcoal-filtered Cigarettes on Product Perceptions, Smoking Behaviors, and Toxicant Exposure","Inclusion Criteria:\n\n* Eligible subjects will be:\n\n  1. Male and female smokers who are at least 21 years of age and self-report smoking at least 5 cigarettes per day for at least the past 6 months.\n  2. Smokers of primarily non-menthol cigarettes of brands other than Natural American Spirit.\n  3. Not currently undergoing smoking cessation treatment or trying to quit.\n  4. Able to communicate fluently in English (speaking, writing, and reading).\n  5. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form.\n\nExclusion Criteria:\n\n* Subjects who self-report and\u002For present with the following criteria will not be eligible to participate in the study:\n\nSmoking Behavior\n\n1. Use of menthol or Natural American Spirit cigarettes as preferred\u002Fregular brand (defined as using \\>20% of the time).\n2. Enrollment or plans to enroll in a smoking cessation program in the next month.\n3. Provide an initial Carbon Monoxide (CO) reading \\\u003C 5 parts per million (ppm).\n\nAlcohol\u002FDrugs\n\n1. History of substance abuse (other than nicotine) in the past 12 months and\u002For currently receiving medical treatment for substance abuse.\n2. Current alcohol consumption that exceeds 25 standard drinks\u002Fweek.\n\nMedical\n\n1. Women who are pregnant, planning a pregnancy, and\u002For lactating.\n2. Any impairment including, but not limited to, visual, physical, and\u002For neurological impairments preventing the completion of procedures included within this protocol. Notable impairments will be evaluated by the PI and eligibility will be determined on a case-by-case basis.\n3. Color blindness.\n4. Serious or unstable disease within the past 12 months (e.g. heart disease, cancer). Applicable conditions will be evaluated by the Principal Investigator and eligibility will be determined on a case-by-case basis.\n\nPsychiatric\n\nAs determined by self-report:\n\n1. Lifetime history or current diagnosis of psychosis, bipolar disorder, and\u002For schizophrenia.\n2. Current diagnosis of major depression. Subjects with a history of major depression, in remission for 6 months or longer, are considered eligible.\n\nOther\n\nAdditionally, participants may be deemed ineligible for any of the following general reasons at any point throughout the study, as well as during the initial telephone screen, at the discretion of the PI:\n\n* Significant non-compliance with protocol and\u002For study design.\n* Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact study data.\n* Any medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance.","21 Years",{"count":534,"type":20},252,[56],"The overall purpose of this study is to determine the effects of using charcoal-filtered cigarettes on product perceptions, smoking behaviors, and biomarkers of exposure to tobacco-related toxicants. The main questions it aims to answer are:\n\nDo perceptions of cigarettes differ by their filter? Do people smoke charcoal-filtered cigarettes differently than cigarettes with conventional filters, and does this change their exposure to cigarette harms?\n\nStudy participants will complete a 5-week laboratory-based, open-label, parallel-design randomized trial. After a baseline period of smoking their preferred brand, participants will smoke charcoal-filtered or non-charcoal-filtered cigarettes for 4 weeks while completing weekly sessions to assess primary outcomes. During weekly sessions, they will smoke two cigarettes in our laboratory, provide urine and carbon monoxide samples, and complete questionnaires.",[538],"Smoking ( Cigarette)",[540,541,542,543,544],"smoking behavior","charcoal","cigarette filter","perceptions","biomarkers",{"date":546,"type":35},"2026-06-05",{"date":548,"type":35},"2026-04-27",{"date":550,"type":20},"2030-12-31",{"name":41,"class":42},{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":191,"minAge":17,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":21,"phases":562,"briefSummary":563,"conditions":564,"keywords":567,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":577,"completionDateStruct":578,"leadSponsor":579,"locationsCount":4},"100611692","mobile-based-obstetric-monitoring-for-pregnancies-complicated-by-hypertension-andor-diabetes-mom-hd-100611692","NCT07243886","Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and\u002For Diabetes (MOM-HD)","Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and\u002For Diabetes (MOM-HD): a Type II Hybrid Implementation-Effectiveness Trial","MOM-HD","Inclusion Criteria:\n\n* Pregnant women receiving antenatal care at RCT site\n* Diagnosed with one of the following:\n\n  * Chronic hypertension (sustained systolic BP ≥140 mm Hg and\u002For diastolic BP ≥90 mm Hg, or on antihypertensive treatment before 20 weeks of gestation)\n  * Gestational hypertension or preeclampsia without severe features (sustained systolic BP ≥140 mm Hg and\u002For diastolic BP ≥90 mm Hg after 20 weeks of gestation)\n  * Gestational diabetes\n* Age 18 years or older\n* Access to a smartphone\n* Gestational age ≤ 34 weeks at enrollment\n\nExclusion Criteria:\n\n* Multifetal pregnancies\n* Apparent communication difficulties (e.g., hearing, speech, or cognitive impairments), as judged by research assistants\n* Unable to understand the Nepali language\n* Severe maternal illness or any condition that precludes active study participation (e.g., preeclampsia with severe features, eclampsia, HELLP syndrome, or other conditions requiring inpatient management)\n* Declines to provide informed consent",{"count":561,"type":20},864,[56],"Hypertensive disorders during pregnancy (HDP) and gestational diabetes (GDM) are among the leading complications in pregnancy, significantly contributing to global maternal and fetal morbidity and mortality. (1,2,3) Effective management of HDP and GDM hinges on regular monitoring of blood pressure (BP) and blood glucose (BG) to ensure adequate control and timely interventions for maternal and fetal well-being. Telemonitoring offers a promising and cost-effective alternative by enabling pregnant individuals to monitor BP and BG at home and share real-time results with healthcare providers, facilitating informed clinical decision-making and timely interventions.\n\nHere the investigators propose to conduct a Hybrid Type II Effectiveness-Implementation Randomized Controlled Trial (RCT) to assess the effectiveness and evaluate the implementation of the MOM-HD (Mobile-based Obstetric Monitoring for Hypertension and\u002For Diabetes) program, a mobile app-based perinatal telemonitoring program, in real-world clinical settings in Nepal. To address the study aims, the investigators will recruit 864 women who are newly diagnosed with HDP and GDM from three metropolitan hospitals and randomly assign them to either (i) MOM-HD + standard care or (ii) standard care alone, from enrolment in pregnancy to 6 weeks postpartum. Primary and secondary clinical outcomes will be assessed at delivery, and at 6 weeks postpartum. The investigators hypothesize that compared to standard care, the use of MOM-HD in addition to standard care will result in lower systolic BP levels, lower incidence rate for the composite adverse perinatal outcome of either perinatal loss, neonatal intensive care unit admission, primary cesarean delivery or labor induction, and lower proportion of days with elevated systolic BP or BG readings between recruitment and 6 weeks postpartum. A convergent mixed-methods approach will be used to assess implementation and maintenance outcomes using the RE-AIM framework (4), and economic sustainability will be assessed by collecting primary cost data.",[565,566],"Gestational Diabetes","Hypertensive Disorder of Pregnancy",[568,569,570,571,572,573,574],"pregnancy","telemonitoring","mHealth","GDM","HDP","Nepal","implementation","2026-06-03",{"date":546,"type":35},{"date":37,"type":20},{"date":550,"type":20},{"name":41,"class":42},{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":106,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":587,"targetDuration":4,"studyType":21,"phases":589,"briefSummary":590,"conditions":591,"keywords":593,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":129},"100549939","craving--decision-making-100549939","NCT06440577","Craving & Decision-Making","Decision Neuroscience of Craving","Inclusion Criteria:\n\n* At least 18 years of age\n* Willingness to follow study requirements, as evidenced by an ability to provide written informed consent and read, understand, and complete the study procedures\n* Minimum of 6th grade reading level\n\nAdditional inclusion criteria for participants with OUD:\n\n* Primary diagnosis of OUD encompassing heroin and\u002For painkiller use\n* Receiving medications for OUD treatment on an outpatient basis\n* At least 12-month history of opioid use\n\nExclusion Criteria:\n\n* Unable to speak or read English\n* Active psychosis or mania\n* Current or past schizophrenia diagnosis\n* History of intellectual disability or developmental or neurological disorder, seizures or epilepsy, or loss consciousness lasting more than 30 minutes\n* Severe medical conditions requiring hospitalization or that, in the opinion of the study staff could compromise study participation\n* MRI contraindications (claustrophobia, nonremovable piercings, certain metal in the body etc.) or pregnancy\n\nAdditional exclusion criteria for community control participants:\n\n* Positive urine drug screen\n* Current or past problematic substance use other than nicotine, and alcohol abuse confined to college or military service\n* Current or past bipolar disorder diagnosis\n* Use of central nervous system medications within the past 6 weeks (e.g., antidepressants, Ritalin)",{"count":588,"type":20},160,[56],"Craving is the strong desire for something, such as for substances in drug addiction and food or other activities in everyday life. Recent work suggests craving can influence how people make decisions and assign value to choice options available to them, yet the neural mechanisms underlying these interactions between craving and valuation remain unknown. To address this, this study uses cognitive decision-making tasks that measure how much individuals will pay (from a study endowment) to have everyday consumer items or snack foods when they crave something specific (opioids or a specific snack, respectively). First, the study will identify the neural mechanisms for how drug craving (craving for opioids) interacts with valuation for consumer items that have associations with drug use or not in people receiving treatment for opioid use disorder (OUD). This will be evaluated in the activity patterns and interactions among brain regions involved in craving and value assignment during decision-making. Then, the study will examine for parallel mechanisms for how food craving (craving for a specific snack) interacts with valuation for snack food items that have similar features to the craved snack or not in people receiving treatment for OUD and non-psychiatric community control participants.",[592],"Decision Making",[594,592,595,596],"Craving","Opioid Use Disorder","Dietary Choice","2026-06-02",{"date":518,"type":35},{"date":600,"type":35},"2024-06-18",{"date":602,"type":20},"2027-12",{"name":41,"class":42},{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":4,"eligibilityCriteria":610,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":611,"targetDuration":4,"studyType":21,"phases":613,"briefSummary":614,"conditions":615,"keywords":618,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":629},"100471487","phase-2-palliative-dose-escalated-radiation-for-painful-non-spine-bone-metastases-and-painful-non-bone-metas-100471487","NCT05419518","Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas","Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metastases","Inclusion Criteria:\n\n* Have provided signed informed consent for the trial\n* Aged ≥18 years at the time of informed consent\n* Histologic proof of malignancy\n* Radiologic or histologic evidence of bone metastases or non-bone metastases\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of ≥3\n* Pain Score ≥ 3\n* Life expectancy of six months or more\n* Willing and able to comply with all aspects of the protocol\n* A female participant is eligible to participate if she is not pregnant and not breastfeeding\n* Woman of childbearing potential who agrees to follow contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.\n* A male participant must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment.\n\nExclusion Criteria:\n\n* Metastasis from a highly radiosensitive tumor (eg, lymphoma, myeloma, germ cell tumor)\n* Spinal metastasis\n* Active compression of spinal cord\u002Fcauda equina\n* Previous RT or SBRT to the same site\n* \\> 3 sites requiring radiation treatment",{"count":612,"type":20},124,[166],"The investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 40-50% in painful non-spinal bone metastases. Additionally, the investigators hypothesize that utilizing a fractionation scheme with an escalated biologically equivalent dose (BED) will result in a higher proportion of participants responding to treatment, and will also lead to more durable responses. Furthermore, the investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 35-45% in painful non-bone metastases",[616,617],"Neoplasm Metastases","Metastases, Neoplasm",[619,620,621],"Metastase","Bone Neoplasms","Dose Fractionation, Radiation","2026-05-29",{"date":597,"type":35},{"date":625,"type":35},"2023-03-16",{"date":627,"type":20},"2027-04-01",{"name":41,"class":42},7,{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":4,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":637,"targetDuration":4,"studyType":21,"phases":639,"briefSummary":640,"conditions":641,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":73},"100378723","early-phase-1-loratadine-for-the-reduction-of-g-csf-induced-bone-pain-in-patients-with-multiple-myeloma-undergoing-stem-cell-mobilization-100378723","NCT04211259","Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization","The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization","Inclusion Criteria:\n\n* Patient must be able to provide informed consent\n* Patients with confirmed diagnosis of multiple myeloma\n* Able to swallow and retain oral medication\n* All ethnic groups are eligible\n\nExclusion Criteria:\n\n* Non-English speaking person\n* Patients undergoing haploidentical allogeneic hematopoietic stem cell transplant\n* Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds\n* Any medical complications or conditions that would, in the investigator's judgement, interfere with full participation in the study\n* On therapeutic dose of aspirin (doses greater than 81 mg) within 7 days prior to the start of the study",{"count":638,"type":20},70,[266],"This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.",[642],"Plasma Cell Myeloma","2026-05-26",{"date":622,"type":35},{"date":646,"type":35},"2022-04-18",{"date":648,"type":20},"2027-06-30",{"name":41,"class":42},{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":656,"eligibilityCriteria":657,"healthyVolunteers":106,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":658,"targetDuration":4,"studyType":660,"phases":4,"briefSummary":661,"conditions":662,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":666,"lastUpdatePostDateStruct":667,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":129},"100575562","rutgers-university-study-of-the-genetics-of-breast-cancer-100575562","NCT06773897","Rutgers University Study of the Genetics of Breast Cancer.","The Rutgers University Genetics Coordinating Center Breast Cancer Study","RUGCC-BC","Inclusion Criteria:\n\n* age 18 years or older\n* currently living in the United States\n* able to understand and follow written instructions in English\n* have access to the internet and a computer, laptop, tablet or smart phone\n* willing to provide written informed consent for participation\n* willing to provide DNA via a saliva sample using a collection kit mailed to the study participant's home\n* willing to complete a survey with questions about health related to the study of breast cancer.\n\nExclusion Criteria:\n\n* Not able to meet or fulfill any of the inclusion criteria",{"count":659,"type":20},25000,"OBSERVATIONAL","The goal of this observational study is to learn more about how genes impact the risk of breast cancer. Anyone 18 or older living in the US is eligible, and a diagnosis of cancer is NOT required. Study participation is online, and it takes about 20 minutes to complete health surveys and request a saliva collection kit sent through US mail. In return, study participants may opt to receive information about their genetic ancestry at no cost.",[663,664,665],"Breast Cancer Risk","Breast Cancer Prevention","Breast Cancer","2026-05-21",{"date":668,"type":35},"2026-05-22",{"date":670,"type":35},"2024-04-15",{"date":672,"type":20},"2028-04-30",{"name":41,"class":42},""]